Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Eva, Juengel"'
Autor:
Olesya Vakhrusheva, Holger H. H. Erb, Vitus Bräunig, Sascha D. Markowitsch, Patricia Schupp, Patrick C. Baer, Kimberly Sue Slade, Anita Thomas, Igor Tsaur, Martin Puhr, Zoran Culig, Jindrich Cinatl, Martin Michaelis, Thomas Efferth, Axel Haferkamp, Eva Juengel
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Novel therapeutic strategies are urgently needed for advanced metastatic prostate cancer (PCa). Phytochemicals used in Traditional Chinese Medicine seem to exhibit tumor suppressive properties. Therefore, the therapeutic potential of artesunate (ART)
Externí odkaz:
https://doaj.org/article/e8bf3189c0f242e381ae779a1a745f9c
Autor:
Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K.-H. Chun, Roman A. Blaheta
Publikováno v:
Biomedicines, Vol 9, Iss 11, p 1630 (2021)
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been es
Externí odkaz:
https://doaj.org/article/d658e594097e425e983507c22ab51534
Autor:
Igor Tsaur, Anita Thomas, Eva Juengel, Sebastian Maxeiner, Timothy Grein, Quynh Chi Le, Veronika Muschta, Jochen Rutz, Felix K. H. Chun, Roman A. Blaheta
Publikováno v:
Biology, Vol 10, Iss 10, p 1007 (2021)
The serum level of soluble (s)E-cadherin is elevated in several malignancies, including prostate cancer (PCa). This study was designed to investigate the effects of sE-cadherin on the behavior of PCa cells in vitro, with the aim of identifying a pote
Externí odkaz:
https://doaj.org/article/4096ec2ba66a4e37835f6aa48dba26ac
Autor:
Holger H H Erb, Julia Bodenbender, Florian Handle, Tamara Diehl, Lukas Donix, Igor Tsaur, Martin Gleave, Axel Haferkamp, Johannes Huber, Susanne Fuessel, Eva Juengel, Zoran Culig, Christian Thomas
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237248 (2020)
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of trans
Externí odkaz:
https://doaj.org/article/4e67266c59d74563ae1dc628b1acd121
Autor:
Fuguang Zhao, Olesya Vakhrusheva, Sascha D. Markowitsch, Kimberly S. Slade, Igor Tsaur, Jindrich Cinatl, Martin Michaelis, Thomas Efferth, Axel Haferkamp, Eva Juengel
Publikováno v:
Cells, Vol 9, Iss 12, p 2643 (2020)
Cisplatin, which induces DNA damage, is standard chemotherapy for advanced bladder cancer (BCa). However, efficacy is limited due to resistance development. Since artesunate (ART), a derivative of artemisinin originating from Traditional Chinese Medi
Externí odkaz:
https://doaj.org/article/81cba9c277f645ea852ac5d50fd2a109
Autor:
Hui Xie, Jochen Rutz, Sebastian Maxeiner, Timothy Grein, Anita Thomas, Eva Juengel, Felix K.-H. Chun, Jindrich Cinatl, Axel Haferkamp, Igor Tsaur, Roman A. Blaheta
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4682
Combined cisplatin–gemcitabine (GC) application is standard for treating muscle-invasive bladder cancer. However, since rapid resistance to treatment often develops, many patients turn to supplements in the form of plant-based compounds. Sulforapha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::585b792d931d662582ef8afae6864a71
Autor:
Eva Juengel, Jasmina Makarević, Michael Reiter, Jens Mani, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 4, Pp 291-300 (2014)
Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma (RCC). However, chronic drug exposure may trigger resistance, limiting the utility of these agents. The metastatic behavior of RCC cells, susce
Externí odkaz:
https://doaj.org/article/fff53da712ce4e9790e0809b4b438f46
Autor:
Anita Thomas, Shirine Huck, Kimberly Slade, Olesya Vakhrusheva, Martin Michaelis, Jaroslav Jinatl, Florian Rothweiler, Axel Haferkamp, Eva Juengel, Jindrich Cinatl, Igor Tsaur
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f2d67c98f2a17baf9a5c142c337260a
https://doi.org/10.1097/ju.0000000000002612.20
https://doi.org/10.1097/ju.0000000000002612.20
Autor:
Kai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, Wolfgang Eberhardt, Michel Mittelbronn, Patrick N. Harter, Eva Juengel, Roman Blaheta, Josef Pfeilschifter, Paul Gutwein
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 2, Pp 218-230 (2013)
A disintegrin and metalloproteinase 17 (ADAM17) is a metalloprotease that is overexpressed in many cancer types, including renal cancers. However, the regulatory mechanisms of ADAM17 in cancer development and progression are poorly understood. In the
Externí odkaz:
https://doaj.org/article/df4b2e17e8f94f12b8b8feaa96d6cefd
Autor:
Stefanie N Brunner, Nicolai V Bogert, Andreas A Schnitzbauer, Eva Juengel, Anton Moritz, Isabella Werner, Angela Kornberger, Andres Beiras-Fernandez
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187839 (2017)
Ischemia-reperfusion injury (IRI) is a major challenge in liver transplantation. The mitochondrial pathway plays a pivotal role in hepatic IRI. Levosimendan, a calcium channel sensitizer, was shown to attenuate apoptosis after IRI in animal livers. T
Externí odkaz:
https://doaj.org/article/7ce8ffdfc53145108502a80ea8437ce0